News & Updates
Filter by Specialty:
Intensive BP management reduces CVD deaths in overweight, obese patients
Intensive management of blood pressure (BP) leads to a significant reduction in cardiovascular events in overweight, obese I, and obese II patients without elevating safety risks, a study has shown.
Intensive BP management reduces CVD deaths in overweight, obese patients
23 May 2022
Keto diet: Is there good evidence in MS?
A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.
Keto diet: Is there good evidence in MS?
23 May 2022
Which canagliflozin dose is best for T2DM patients with hypertension?
A recent meta-analysis offers new proof of different canagliflozin doses for hypertension management in patients with type 2 diabetes mellitus (T2DM) complicated by hypertension. However, low-density lipoprotein cholesterol (LDL-C) and the risk of urinary tract infection must be observed.
Which canagliflozin dose is best for T2DM patients with hypertension?
22 May 2022
Male sex, obesity among risk factors for severe COVID-19 in children
A large study by the US National COVID Cohort Collaborative (N3C) has identified factors associated with the risk of severe disease among children with SARS-CoV-2 infection as well as factors tied to an increased risk of multisystem inflammatory syndrome in children (MIS-C) as compared to acute COVID-19.
Male sex, obesity among risk factors for severe COVID-19 in children
20 May 2022
Multi-metal exposure ups diabetes mellitus risk
Exposure to different metals, particularly cadmium, iron, zinc, copper, and lead, appears to aggravate the risks of impaired fasting glucose (IFG) and diabetes mellitus, reports a recent China study.
Multi-metal exposure ups diabetes mellitus risk
19 May 2022
SGLT2i beats DPP4i at reducing cardiovascular disease in type 2 diabetes
Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i) leads to lower rates of cardiovascular disease (CVD) events in patients with type 2 diabetes mellitus (T2DM) than does dipeptidyl peptidase-4 inhibitors (DPP4i), reports a recent Japan study.
